FREE PHENOWEBINARS
Characterizing Antibody-Oligonucleotide Conjugates (AOCs) Under Native SEC-MS Conditions
Speaker:
Roxana Eggleston-Rangel
Senior Applications Scientist, Phenomenex
Roxana joined Phenomenex in 2018 as an Applications Scientist and is currently working with the applications team to produce analytical solutions for the biopharma industry. Her current work focuses on characterization of mRNA, sgRNA and siRNA. Prior to Phenomenex, Roxana worked for Caltech and the University of Southern California developing LM-CS workflows for the proteomics community. She received her bachelor’s and master’s degree in Chemistry and Biochemistry from California State University, Los Angeles.
One webinar, two viewing options
We know you're busy, select a viewing session that works best for you.
Viewing Options
Session 1
Tuesday, March 24, 2026
Los Angeles: 10:00 AM PT | New York: 1:00 PM EST
Mexico City: 12:00 PM CDT
Session 2
Wednesday, March 25, 2026
London: 9:00 AM GMT | Berlin: 10:00 AM CET
Mumbai: 2:30 PM IST
Overview
Antibody–oligonucleotide conjugates (AOCs) combine antibody specificity with oligonucleotide precision, offering a promising therapeutic platform. Accurate oligo-to-antibody ratio (OAR) determination is essential for efficacy and safety, yet conventional hydrophobic interaction chromatography (HIC) fails due to the hydrophilic, polyanionic nature of oligonucleotides, which masks hydrophobic differences. Native size-exclusion chromatography coupled with mass spectrometry (SEC-MS) has emerged as a robust approach for intact AOC analysis, enabling OAR distribution and aggregate detection. This webinar will showcase an SEC-MS method developed to characterize AOCs composed of a trastuzumab biosimilar conjugated with siRNA.
Key Learning Points
- Understand the structure of an antibody-oligo conjugate (AOC) and its components.
- Identify the analytical requirements and challenges of AOC characterization.
- Explore LC with MS and UV strategies for AOC characterization.
Who Should Attend
- Scientists who are performing analytical LC method development for antibody-oligo conjugate, associated free siRNA, and associated free antibody.
